In order for cell therapies to scale effectively, the industry is clamouring for standardisation around things like manufacturing and treatment administration.
Innovative, advanced therapies have enormous promise, but also come with a host of logistical problems that innovators underestimate at their own peril.
AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.